Hansa Biopharma AB (SE:HNSA)
:HNSA
HNSA Stock Chart & Stats
kr32.68
-kr0.04(-0.17%)
At close: 4:00 PM EST
kr32.68
-kr0.04(-0.17%)
Day’s Range― - ―
52-Week Rangekr19.58 - kr42.98
Previous CloseN/A
Volume97.73K
Average Volume (3M)792.96K
Market Cap
kr3.33B
Enterprise Valuekr2.89B
Total Cash (Recent Filing)kr701.08M
Total Debt (Recent Filing)kr933.82M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Apr 23, 2026EPS Estimate
-1.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding101,763,220
10 Day Avg. Volume714,369
30 Day Avg. Volume792,961
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)-31.35
Price to Sales (P/S)12.55
P/FCF Ratio-5.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr103.00Price Target Upside215.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-6.05
Revenue Forecast (FY)kr280.21M
Bulls Say, Bears Say
Bulls Say
Addressable Patient PopulationImlifidase could enable highly sensitized transplant patients to receive a wider range of donor organs, addressing a substantial unmet medical need and supporting demand for the therapy.
Clinical Evidence And Surrogate EndpointUse of the eGFR kidney function surrogate together with ConfIdeS trial outcomes showing graft function comparable to typical transplant patients strengthens the evidentiary case for approval and suggests potential for sustained graft survival.
European Commercial TractionRecorded sales across major European markets and secured reimbursement in multiple countries indicate expanding commercial traction and potential revenue growth in Europe.
Bears Say
Clinical Data QualityAn imbalance in transplanted patients between treatment and control groups in the clinical dataset is likely to prompt extra regulatory scrutiny and could complicate approval decisions.
Partnership And Revenue RiskTermination of a partnered gene therapy trial removed expected milestone payments, reducing near-term cash inflows and prompting analysts to lower price targets.
Regulatory Timeline RiskFDA assignment of a standard review instead of a priority review implies a longer regulatory timeline and increases uncertainty around the timing of a potential approval.
Hansa Biopharma AB News
HNSA FAQ
What was Hansa Biopharma AB’s price range in the past 12 months?
Hansa Biopharma AB lowest stock price was kr19.58 and its highest was kr42.98 in the past 12 months.
What is Hansa Biopharma AB’s market cap?
Hansa Biopharma AB’s market cap is kr3.33B.
When is Hansa Biopharma AB’s upcoming earnings report date?
Hansa Biopharma AB’s upcoming earnings report date is Apr 23, 2026 which is in 16 days.
How were Hansa Biopharma AB’s earnings last quarter?
Hansa Biopharma AB released its earnings results on Feb 11, 2026. The company reported -kr1.62 earnings per share for the quarter, missing the consensus estimate of -kr1.576 by -kr0.044.
Is Hansa Biopharma AB overvalued?
According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued.
Does Hansa Biopharma AB pay dividends?
Hansa Biopharma AB does not currently pay dividends.
What is Hansa Biopharma AB’s EPS estimate?
Hansa Biopharma AB’s EPS estimate is -1.45.
How many shares outstanding does Hansa Biopharma AB have?
Hansa Biopharma AB has 101,763,220 shares outstanding.
What happened to Hansa Biopharma AB’s price movement after its last earnings report?
Hansa Biopharma AB reported an EPS of -kr1.62 in its last earnings report, missing expectations of -kr1.576. Following the earnings report the stock price went up 4.759%.
Which hedge fund is a major shareholder of Hansa Biopharma AB?
Currently, no hedge funds are holding shares in SE:HNSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
HNSA Stock 12 Month Forecast
Average Price Target
kr103.00
▲(215.18% Upside)
Technical Analysis
BioInvent International AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---